Linear Clinical Research | Perth, Australia
Status and phase
Conditions
Treatments
About
This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
24 participants in 3 patient groups
Loading...
Central trial contact
Carina Freedman
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal